Yan-Ling Zhang

Yan-Ling Zhang is director of in vitro pharmacology in the Therapeutics Platform at the Broad Institute. In this role, Zhang focuses on the development of biologically relevant high-throughput biochemical and phenotypic assays to enable high-throughput screening (HTS) for a variety of drug targets for psychiatric disorders. She is currently interested in developing a high-throughput calcium dynamics assay to monitor synaptic networks. Trained as an enzymologist, Zhang has expertise in inhibition kinetics and mechanism of action studies for HTS hits and lead compounds

Before joining the Broad, Zhang led an enzymology group for assay development and hit validation at Wyeth Research from 2001 to 2007. She also helped build the biophysical capabilities for lead compound characterization at Merck Research Laboratories in Boston from 2007 to 2009.

Zhang received a bachelor’s degree in radiochemistry from Lanzhou University, a master’s degree in nuclear chemistry from China Institute of Atomic Energy, and a Ph.D. in biochemistry/enzymology from Institute of Biophysics, Chinese Academy of Sciences. She completed postdoctoral work in enzyme structure and function at Michigan State University and Albert Einstein College of Medicine.
 

Last updated date: January 2014